Geron (NASDAQ: GERN) stock is getting crushed in Wednesday's trading. The company's share price was down 31.7% as of 3:50 p.m ...

Geron Corporation's stock dropped 50% before its Q4 2024 earnings report, with Rytelo's revenue close to projections but new ...

Wedbush is removing Geron (GERN) from the firm’s Best Ideas List due to its investment price discipline. Wedbush has an Outperform rating on ...

Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course ...

Shares of Geron (NASDAQ:GERN) plunged 30% early Wednesday after the company released its Q4 earnings report. Geron reported a ...

Barclays analyst Peter Lawson lowered the firm’s price target on Geron (GERN) to $4 from $9 and keeps an Overweight rating on the shares post ...

Geron shares fell 30% to $1.66 after the company reported a fourth-quarter loss that was wider than expected.

B. Riley dropped their FY2025 earnings per share (EPS) estimates for shares of Geron in a research report issued to clients ...

FOSTER CITY, Calif. (AP) — FOSTER CITY, Calif. (AP) — Geron Corp. (GERN) on Wednesday reported a loss of $25.4 million in its fourth quarter. The Foster City, California-based company said it had a ...

Geron (NASDAQ: GERN) stock is getting crushed in Wednesday's trading. The company's share price was down 31.7% as of 3:50 p.m. ET and had been down as much as 38.7% earlier in the session.

"2024 was a terrific year for Geron and for RYTELO, our first-in-class telomerase inhibitor, which we believe represents a highly differentiated treatment with blockbuster potential in the high ...

Geron stock is seeing a dramatic pullback following the company's fourth-quarter report. Geron's earnings in Q4 fell short of Wall Street's expectations, and management had worrying guidance for ...